Literature DB >> 19465849

Colon cancer screening and surveillance controversies.

David Lieberman1.   

Abstract

PURPOSE OF REVIEW: To discuss new colorectal cancer screening tests and highlight controversies regarding colon screening and surveillance. RECENT
FINDINGS: New screening guidelines were published in 2008. Tests that primarily detect early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test. Tests that can detect both early cancer and cancer precursor lesions include sigmoidoscopy and colonoscopy. One guideline endorses the use of computed tomographic colonography. Limitations of each test are highlighted in the new guidelines. Controversies include age to start screening, age to stop screening, and appropriate interval after a negative screening colonoscopy. New work has raised some doubt about the protective effect of colonoscopy in the proximal colon. Finally, there is new emphasis on the quality of screening programs.
SUMMARY: Colorectal cancer screening can reduce both incidence and mortality of colorectal cancer if performed with high quality. New work should focus on improving the quality of all screening programs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465849     DOI: 10.1097/MOG.0b013e32832d1e2a

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  9 in total

1.  Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty.

Authors:  Nancy N Baxter; Joan L Warren; Michael J Barrett; Therese A Stukel; V Paul Doria-Rose
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

2.  Small bowel evaluation in asymptomatic fecal immunochemical test-positive patients with a negative colonoscopy: is it necessary?

Authors:  Jae Jun Park; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2011-10       Impact factor: 3.199

3.  Insights in public health: public health perspectives on colorectal cancer screening.

Authors:  Ranjani R Starr; Florlinda V Taflinger; Christina M Teel
Journal:  Hawaii J Med Public Health       Date:  2014-07

4.  The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening.

Authors:  Aurelien Amiot; Hicham Mansour; Isabelle Baumgaertner; Jean-Charles Delchier; Christophe Tournigand; Jean-Pierre Furet; Jean-Pierre Carrau; Florence Canoui-Poitrine; Iradj Sobhani
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

5.  The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test.

Authors:  Maryam Mousavinezhad; Reza Majdzadeh; Ali Akbari Sari; Alireza Delavari; Farideh Mohtasham
Journal:  Med J Islam Repub Iran       Date:  2016-05-09

Review 6.  Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?

Authors:  Alexandre Loktionov
Journal:  World J Gastrointest Oncol       Date:  2020-02-15

7.  Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.

Authors:  Kinga Tóth; Ferenc Sipos; Alexandra Kalmár; Arpád V Patai; Barnabás Wichmann; Robert Stoehr; Henriette Golcher; Vera Schellerer; Zsolt Tulassay; Béla Molnár
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

8.  MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.

Authors:  Kyungjin Lee; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

Review 9.  Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives.

Authors:  Gianluca Pellino; Gaetano Gallo; Pierlorenzo Pallante; Raffaella Capasso; Alfonso De Stefano; Isacco Maretto; Umberto Malapelle; Shengyang Qiu; Stella Nikolaou; Andrea Barina; Giuseppe Clerico; Alfonso Reginelli; Antonio Giuliani; Guido Sciaudone; Christos Kontovounisios; Luca Brunese; Mario Trompetto; Francesco Selvaggi
Journal:  Gastroenterol Res Pract       Date:  2018-06-13       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.